Page last updated: 2024-12-07

tryptophan methyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tryptophan methyl ester (Trp-OMe) is a derivative of the amino acid tryptophan, where the carboxyl group is replaced with a methyl ester. It is a key intermediate in the synthesis of various tryptophan-containing compounds and is often used as a building block in peptide synthesis. Research suggests that Trp-OMe might exhibit neuroprotective effects, possibly by acting as a precursor to serotonin, an important neurotransmitter. It is also under investigation for its potential role in treating conditions related to inflammation and oxidative stress. However, more research is needed to understand its specific mechanisms of action and potential therapeutic applications.'

tryptophan methyl ester: RN given refers to parent cpd(DL)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122205
CHEMBL ID5189584
SCHEMBL ID1195735
SCHEMBL ID19161138
MeSH IDM0090839

Synonyms (36)

Synonym
ENAMINE_005721
CBDIVE_001180
IDI1_007956
methyl 2-amino-3-(1h-indol-3-yl)propanoate
MAYBRIDGE1_006748
STK503769
methyl tryptophanate
AKOS000506157
HMS1410E01
dl-tryptophan methyl ester
7303-49-3
dl-tryptophan, methyl ester
tryptophan methyl ester
l-tryptophan methyl ester, 14
bdbm92692
AB03267
AKOS016345430
SCHEMBL1195735
tryptophan methylester
dl-tryptophane methyl ester
dl-tryptophan methyl
KCUNTYMNJVXYKZ-UHFFFAOYSA-N
AG-205/03650008
mfcd00090478
methyl 2-amino-3-(1h-indol-3-yl)propanoate (h-dl-trp-ome)
CHEMBL5189584
SCHEMBL19161138
VS-14426
BBL037751
tryptophan, methyl ester, l- (6ci,7ci,8ci); (s)-2-amino-3-(1h-indol-3-yl)propionic acid methyl ester; l-tryptophan methyl ester; l-tryptophane methyl ester; methyl l-tryptophanate; s-tryptophan methyl este
A923774
methyl2-amino-3-(1h-indol-3-yl)propanoate
EN300-34069
DTXSID40864547
mfcd08669786
SY317022

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Oral administration of D-1MT in rats from 150 to 3000 mg/m(2)/day (25-500 mg/kg/day) and in dogs from 600 to 1200 mg/m(2)/day (30 and 60 mg/kg/day) for 28 consecutive days did not lead to mortality, adverse events, histopathological lesions, or significant changes in hematology, clinical chemistry, and body weight."( Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption.
Ames, MM; Buhrow, SA; Jia, L; Munn, DH; Noker, PE; Page, JG; Reid, JM; Schweikart, K; Tomaszewski, J, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
" The cytotoxicity of T cells induced by MSC-secreting Tandab (CD3/CD19) was detected in vitro and in vivo in combination with D-1-methyl-tryptophan (D-1MT), an IDO pathway inhibitor."( Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
Fan, D; Lu, Y; Xiong, D; Yang, Y; Ye, Z; Zhang, L; Zhang, Q; Zhang, X; Zhang, Y, 2017
)
0.46
" And mice injected with MSC-Tandab in combination with D-1MT significantly inhibited the tumor growth."( Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
Fan, D; Lu, Y; Xiong, D; Yang, Y; Ye, Z; Zhang, L; Zhang, Q; Zhang, X; Zhang, Y, 2017
)
0.46
"These results suggest that UC-MSCs releasing Tandab (CD3/CD19) is an efficient therapeutic tool for the treatment of B cell lymphoma when combined with D-1MT."( Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
Fan, D; Lu, Y; Xiong, D; Yang, Y; Ye, Z; Zhang, L; Zhang, Q; Zhang, X; Zhang, Y, 2017
)
0.46
" Indoleamine 2, 3‑dioxygenase (IDO) is an immunosuppressive, intracellular rate-limiting enzyme, which contributes to immune tolerance in various tumours, including melanoma, and inhibition of IDO may be considered a novel therapeutic strategy when combined with pimozide."( The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
Feng, Y; Feng, Z; Guo, J; Guo, M; Jia, H; Ren, W; Song, X; Tian, Z; Wang, H; Wang, M; Wei, T; Zhao, J; Zhao, T, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
"7 h, a T(max) of 1h and 8h, and a bioavailability of 47% and 92%, respectively."( Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption.
Ames, MM; Buhrow, SA; Jia, L; Munn, DH; Noker, PE; Page, JG; Reid, JM; Schweikart, K; Tomaszewski, J, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
" Mean plasma concentrations of D-1MT (600 and 1200 mg/m(2)/day) in dogs 1h post dosing were 54."( Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption.
Ames, MM; Buhrow, SA; Jia, L; Munn, DH; Noker, PE; Page, JG; Reid, JM; Schweikart, K; Tomaszewski, J, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
regulation of DNA-templated transcriptionTrp operon repressorEscherichia coli K-12
regulation of DNA-templated transcriptionTrp operon repressorEscherichia coli K-12
negative regulation of DNA-templated transcriptionTrp operon repressorEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
DNA bindingTrp operon repressorEscherichia coli K-12
DNA-binding transcription factor activityTrp operon repressorEscherichia coli K-12
sequence-specific DNA bindingTrp operon repressorEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
cytoplasmTrp operon repressorEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1847223Antileishmanial activity against Leishmania donovani Bob intracellular amastigotes assessed as parasite growth inhibition incubated for 72 hrs by LDH assay2021European journal of medicinal chemistry, Nov-05, Volume: 223Recent advancements in anti-leishmanial research: Synthetic strategies and structural activity relationships.
AID1799822Binding Assay from Article : \\The structural basis for the interaction between L-tryptophan and the Escherichia coli trp aporepressor.\\1987The Journal of biological chemistry, Apr-05, Volume: 262, Issue:10
The structural basis for the interaction between L-tryptophan and the Escherichia coli trp aporepressor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (109)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (20.18)18.7374
1990's15 (13.76)18.2507
2000's34 (31.19)29.6817
2010's35 (32.11)24.3611
2020's3 (2.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.42 (24.57)
Research Supply Index4.76 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index41.19 (26.88)
Search Engine Supply Index3.03 (0.95)

This Compound (25.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.87%)5.53%
Reviews3 (2.61%)6.00%
Case Studies1 (0.87%)4.05%
Observational0 (0.00%)0.25%
Other110 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]